Heeg B - Search Results

1

The cost-effectiveness of atypicals in the UK.

Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, de Charro F, van Hout B. Heeg B, et al. Value Health. 2008 Dec;11(7):1007-21. doi: 10.1111/j.1524-4733.2008.00344.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489517 Free article.

2

Modelling the treated course of schizophrenia: development of a discrete event simulation model.

Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJ, de Haan L, van Hout BA. Heeg B, et al. Pharmacoeconomics. 2005;23 Suppl 1:17-33. doi: 10.2165/00019053-200523001-00003. Pharmacoeconomics. 2005. PMID: 16416759

3

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A. Laux G, et al. Among authors: heeg b. Pharmacoeconomics. 2005;23 Suppl 1:49-61. doi: 10.2165/00019053-200523001-00005. Pharmacoeconomics. 2005. PMID: 16416761

4

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

Chue PS, Heeg B, Buskens E, van Hout BA. Chue PS, et al. Among authors: heeg b. Pharmacoeconomics. 2005;23 Suppl 1:62-74. doi: 10.2165/00019053-200523001-00006. Pharmacoeconomics. 2005. PMID: 16416762

5

[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].

Heeg B, van Gestel A, Hout Bv, Olsen J, Haghfelt TH. Heeg B, et al. Ugeskr Laeger. 2006 Aug 28;168(35):2911-5. Ugeskr Laeger. 2006. PMID: 16982022 Danish.

6

Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.

Heeg BM, Peters RJ, Botteman M, van Hout BA. Heeg BM, et al. Pharmacoeconomics. 2007;25(9):769-82. doi: 10.2165/00019053-200725090-00005. Pharmacoeconomics. 2007. PMID: 17803335

7

Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.

Heeg B, Damen J, Van Hout B. Heeg B, et al. Pharmacoeconomics. 2007;25(12):1063-82. doi: 10.2165/00019053-200725120-00007. Pharmacoeconomics. 2007. PMID: 18047390 Review.

8

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.

Heeg BM, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout BA. Heeg BM, et al. Curr Med Res Opin. 2008 Feb;24(2):349-58. doi: 10.1185/030079907x253834. Curr Med Res Opin. 2008. PMID: 18081988

9

Modelling approaches: the case of schizophrenia.

Heeg BM, Damen J, Buskens E, Caleo S, de Charro F, van Hout BA. Heeg BM, et al. Pharmacoeconomics. 2008;26(8):633-48. doi: 10.2165/00019053-200826080-00002. Pharmacoeconomics. 2008. PMID: 18620458

10

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.

Treur M, Heeg B, Möller HJ, Schmeding A, van Hout B. Treur M, et al. Among authors: heeg b. BMC Health Serv Res. 2009 Feb 18;9:32. doi: 10.1186/1472-6963-9-32. BMC Health Serv Res. 2009. PMID: 19226465 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters